|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Non-Small Cell Lung Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma, Non-Small-Cell Lung | |||||
| Lung Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Lung Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Neoplasms | |||||
| Thoracic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| bevacizumab [Avastin] | |||||
| Standard chemotherapy | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Bevacizumab | |||||
| 6 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Hoffmann-La Roche | |||||